Related Experiment Videos
[Clinical study on anti-leukemia effect mediated by dentritic cells]
1Department of Hematopoietic Stem Cell Transplantation, The Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100039, China. chenhu217@sina.com
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|June 24, 2005
Summary
Dendritic cell (DC) immunotherapy is safe and feasible for acute non-lymphocytic leukemia patients post-transplant. This approach significantly improves long-term survival rates and disease-free survival compared to standard care.
Area of Science:
- Immunology
- Oncology
- Cell Therapy
Context:
- Tumor immunotherapy is a key component of modern cancer treatment.
- Dendritic cells (DCs) are potent antigen-presenting cells (APCs) crucial for initiating immune responses against tumors.
- Ex vivo cultured DCs offer a promising avenue for enhancing anti-tumor immunity.
Purpose:
- To evaluate the safety and feasibility of using peripheral blood-derived dendritic cells (DCs) for immunotherapy in patients with acute non-lymphocytic leukemia (ANLL).
- To assess the impact of DC-inducing immunotherapy on the long-term survival of ANLL patients undergoing autologous bone marrow transplantation (ABMT).
Summary:
- Peripheral blood mononuclear cells (PBMNCs) from 13 ANLL patients post-ABMT were cultured ex vivo for 2 weeks to generate DCs.
- DC immunotherapy was administered, and patients were monitored for disease-free survival (DFS).
- Kaplan-Meier analysis revealed a 5-year survival rate of 75.52% in the DC group versus 45.71% in the non-DC group, indicating improved cumulative survival.
Impact:
- Ex vivo cultivation and clinical application of DCs derived from peripheral blood are safe and feasible.
- DC immunotherapy significantly prolongs disease-free survival and enhances long-term survival rates in ANLL patients after ABMT.
- This study supports DC immunotherapy as a valuable strategy in the combined treatment of ANLL.